2008 Therapeutic Temperature Management Congress Opens to Hundreds in Barcelona

Share Article

Leading cardiologists, neurologists, emergency medicine, and other critical-care specialists in attendance; four-day program features review of current clinical research and adopted protocols for use of therapeutic hypothermia and other advanced patient temperature management solutions; a CME-accredited event, unrestricted educational grant support provided to physicians and nurses.

Seeing the congress occur, once again, with the aim of benefitting the many, as opposed to the few, is quite an achievement by all. The best of the best are here, leading the exchange of efforts and ideas in successful therapeutic hypothermia and broader patient temperature applications.

Medavera, Inc. today announced the opening of the 2008 Therapeutic Temperature Management (TTM) Congress in Barcelona, Spain. A still-growing list of cardiologists, neurologists, emergency medicine, and other critical-care specialists are in attendance at the international educational event; also participating is a group of exhibitors and sponsors working in support of global learning.

The event, developed to share up-to-date findings and practices on therapeutic hypothermia and other patient temperature management solutions, is in its second year. This year, with growth in subject awareness and interest, participant points of origin are nearly equally split between North and South America and Europe-Middle East-Asia.

Continuing medical education credit is available to physicians and nurses via sponsorship by the University of Massachusetts Medical School and Medavera. Companies supporting unrestricted educational grants for the TTM Congress include (alphabetically): Alsius, Arizant Healthcare, Cincinnati Sub-Zero (CSZ), Covidien, Gaymar Industries, INNERCOOL therapies, and Medivance®.

It has been clinically proven that proper application of mild therapeutic hypothermia improves neurological outcomes post sudden cardiac arrest. The congress will review research in and protocols for patient temperature modulation treatments post sudden cardiac arrest, as well as traumatic brain, head, and spine injury, stroke and subarachnoid hemorrhage, neonatal asphyxia, and other life-threatening states.

Remarking on the congress, Laura McCaskill, President of Medavera, the conference organizer, said, "This year's event is exactly what we hoped for, what we envisioned. We are gathered in a truly worldwide collaborative outreach effort and the end result is a more knowledgeable and able medical community."

Marvin A. Wayne, MD, FACEP, FAAEM, EMS Medical Director, Bellingham/Whatcom County, Emergency Department, St. Joseph Hospital, Associate Clinical Professor, University of Washington, Investigator in the ResQ Clinical Trial, and a TTM Congress faculty member, specifically will be discussing the subject of patient outcome improvement via the application of therapeutic hypothermia post cardiac arrest.

Said Dr. Wayne, "The ResQ Trial is designed to investigate the benefits of standard cardiopulmonary resuscitation (CPR) versus CPR delivered by two devices, the Cardio Pump and an Impedance Threshold Device in pre-hospital cardiac arrest. Resuscitated patients then are candidates for therapeutic hypothermia on arrival in the Emergency Department. The more we know about the continuum of care, the timing of treatment, and the associated benefits, the sooner we can apply them and the more patients we can ultimately discharge neurologically intact. The TTM Congress helps ensures ongoing advancement of the understanding and adoption of these vital therapies by the medical community."

Mark Beran, Vice President and General Manager of CSZ Medical, an event co-founder and one of the educational sponsors of the event, continued, "Seeing the congress occur, once again, with the aim of benefitting the many, as opposed to the few, is quite an achievement by all. The best of the best are here, leading the exchange of efforts and ideas in successful therapeutic hypothermia and broader patient temperature applications."

The congress is occurring from October 1-4, 2008, in Barcelona, Spain. For more information concerning the congress, please visit http://www.ttmcongress2008.com.

About Medavera:
Medavera, Inc. is a medical education company headquartered in Springfield, MO. The company mission is to improve patient health by identifying educational need and transferring medical knowledge with superior communication strategies and tools. For more information, please visit http://www.medavera.com.

About the Therapeutic Temperature Management Congress:
The Therapeutic Temperature Management (TTM) Congress is an annual international gathering of experts addressing current trends in therapeutic hypothermia and other patient temperature management applications. Leading clinical researchers, physicians, critical-care nurses, and other emergency medicine professionals convene to exchange information and experience in an effort to advance successful protocols in these life-saving treatments. Additional information on the congress is available at http://www.ttmcongress.net.

Forward-Looking Statements:
Except for statements of historical fact, the matters discussed herein are forward-looking, reflect numerous assumptions, and involve risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. We undertake no obligation to release publicly any changes in events or circumstances arising after the date hereof.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura McCaskill
Medavera
417.234.5899
Email >

Ellen Hassett
Visit website